Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Net Income towards Common Stockholders: 2018-2025

Historic Net Income towards Common Stockholders for Bicycle Therapeutics (BCYC) over the last 8 years, with Sep 2025 value amounting to -$59.1 million.

  • Bicycle Therapeutics' Net Income towards Common Stockholders fell 16.33% to -$59.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$250.7 million, marking a year-over-year decrease of 50.75%. This contributed to the annual value of -$169.0 million for FY2024, which is 6.44% up from last year.
  • As of Q3 2025, Bicycle Therapeutics' Net Income towards Common Stockholders stood at -$59.1 million, which was up 25.14% from -$79.0 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Net Income towards Common Stockholders ranged from a high of -$14.7 million in Q3 2021 and a low of -$79.0 million during Q2 2025.
  • Over the past 3 years, Bicycle Therapeutics' median Net Income towards Common Stockholders value was -$49.9 million (recorded in 2023), while the average stood at -$49.9 million.
  • In the last 5 years, Bicycle Therapeutics' Net Income towards Common Stockholders soared by 32.00% in 2024 and then plummeted by 128.72% in 2025.
  • Over the past 5 years, Bicycle Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$18.0 million in 2021, then slumped by 66.20% to -$30.0 million in 2022, then crashed by 63.78% to -$49.1 million in 2023, then decreased by 5.61% to -$51.9 million in 2024, then dropped by 16.33% to -$59.1 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$59.1 million for Q3 2025, versus -$79.0 million for Q2 2025 and -$60.8 million for Q1 2025.